SA
CLDX icon

Sovran Advisors’s Celldex Therapeutics CLDX Stock Holding History

Sovran Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,476
Closed -$842K – 523
2025
Q2 		$842K Buy
+39,476
New +$768K 0.09% 231
2025
Q1 		– Sell
-113,457
Closed -$2.6M – 458
2024
Q4 		$2.6M Buy
+113,457
New +$3.08M 0.37% 70

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sovran Advisors's CLDX Position: Q3 2025 in Review

Sovran Advisors sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 39,476 shares — an estimated $842K sold.

Sovran Advisors first reported a position in CLDX in Q4 2024 and held it in 2 quarters. The position peaked at $2.6M in Q4 2024. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Sovran Advisors reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sovran Advisors sold 39,476 Celldex Therapeutics shares in Q3 2025, an estimated $842K.
  • Sovran Advisors first reported a position in Celldex Therapeutics in Q4 2024 and held it in 2 quarters.
  • Sovran Advisors's Celldex Therapeutics position peaked at $2.6M in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Sovran Advisors's 13F filing for Q3 2025, filed 31 Oct 2025.